lcotrokinra

Icotrokinra (brand name ICOTYDE®) is a first-in-class targeted oral peptide used to treat moderate-to-severe plaque psoriasis in adults and children 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. It works by selectively blocking the interleukin‑23 receptor (IL‑23R), a key immune pathway that drives inflammation in psoriasis. Available as a once‑daily 200 mg tablet taken on an empty stomach, common side effects include headache, nausea, cough, fungal infections, and fatigue.